Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy.

Details

Ressource 1Download: cells-10-02731.pdf (4628.07 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_9DBF7874BCED
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy.
Journal
Cells
Author(s)
Losmanova T., Zens P., Scherz A., Schmid R.A., Tschan M.P., Berezowska S.
ISSN
2073-4409 (Electronic)
ISSN-L
2073-4409
Publication state
Published
Issued date
13/10/2021
Peer-reviewed
Oui
Volume
10
Number
10
Pages
2731
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Abstract
In recent years autophagy has attracted the attention of researchers from many medical fields, including cancer research, and certain anti-macroautophagy drugs in combination with cytotoxic or targeted therapies have entered clinical trials. In the present study, we focused on a less explored subtype of autophagy, i.e., chaperone-mediated autophagy (CMA), with the key proteins LAMP2A and HSPA8 (HSC70), and their immunohistochemical evaluation with previously extensively validated antibodies. We were interested in whether the marker expression is influenced by the antecedent therapy, and its correlation with survival on a cohort of patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy and matched primary resected tumors. In concordance with our previous study, we did not find any intratumoral heterogeneity, nor correlation between the two parameters, nor correlation between the markers and any included pathological parameters. Surprisingly, the expression of both markers was also independent to tumor response or administered neoadjuvant treatment. In the survival analysis, the results were only significant for LAMP2A, where higher levels were associated with longer 5-year overall survival and disease-free survival for the mixed group of adenocarcinomas and squamous cell carcinomas (p < 0.0001 and p = 0.0019 respectively) as well as the squamous cell carcinoma subgroup (p = 0.0001 and p = 0.0001 respectively). LAMP2A was also an independent prognostic marker in univariate and multivariate analysis.
Keywords
Aged, Biomarkers, Tumor/metabolism, Carcinoma, Non-Small-Cell Lung/metabolism, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/therapy, Cell Line, Tumor, Chaperone-Mediated Autophagy, Disease-Free Survival, Female, HSC70 Heat-Shock Proteins/metabolism, Humans, Lung Neoplasms/metabolism, Lung Neoplasms/pathology, Lung Neoplasms/therapy, Lysosomal-Associated Membrane Protein 2/metabolism, Male, Middle Aged, Multivariate Analysis, Neoadjuvant Therapy, HSC70, HSPA8, LAMP2A, chaperone-mediated autophagy (CMA), lung cancer, neoadjuvant therapy, non-small cell lung cancer
Pubmed
Web of science
Open Access
Yes
Create date
26/10/2021 14:55
Last modification date
16/12/2021 6:32
Usage data